Nitto BioPharma

One of our teams met Beata who happened to be wearing one of our scavenger hunt objectives on their shirt! We are very grateful for your help Beata and appreciate your participation in our team building fun!

Nitto BioPharma held it’s 2024 Company Team Building event involving a scavenger hunt around San Diego’s beautiful Balboa Park where the teams had to locate various cultural landmarks and conduct team-based tasks. Besides the fun, the teams learned to strategize, coordinate and manage time, and work together for their success, all while getting to know one another on a more personal level. All the fun was followed with a wonderful luncheon on the roof of the San Diego Museum of Natural History, which is celebrating its 150 year anniversary. The event was a major success with help from our wonderful vendors, and each team enhanced their skills in overcoming challenges to be successful! Thanks Nitto! #OutofOrdinaryGroupAdventures #ContinentalCatering #SDNaturalHistoryMuseum

We're celebrating alongside our Nitto Avecia colleagues as they hold an employee appreciation day. Check back on the Nitto BioPharma company page periodically for upcoming announcements and posts! https://bit.ly/3xdsLD8

Please join Nitto in San Diego from April 5 – 10, 2024 at the AACR Annual Meeting on Molecular Targets and Cancer Therapeutics, to learn about our NBF-006 program targeting GSTP in Patients with KRAS-mutated NSCLC. Exciting results from our groundbreaking study, which has been selected for an oral presentation, will be shared during Dr. Bazhenova’s presentation on April 9th at 3:20 pm. 📅 On April 9, 2024 | Session 2:20 – 4:30 P.M. | HALL GH, Ground Level, SD Convention Center. Dr. Lyudmila Bazhenova, Professor of UCSD Moores Cancer Center, will take the podium to present "First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer". Our innovative approach inhibits GSTP with an siRNA-LNP (NBF-006), inducing anti-proliferative and pro-apoptotic signaling mechanisms within cancer cells. This presentation will provide the results from Phase1 clinical trial of a novel pan-KRAS mechanism of action for the treatment of NSCLC. 📅 On April 10 2024 | 9:00 – 12:30 P.M. | SECTION 24: Nitto will also showcase a poster titled ”Clinical population pharmacokinetic (popPK) analysis of NBF-006, a novel siRNA inhibitor of glutathione-S-transferase P (GSTP) encapsulated in a lipid nano particle (LNP), for treatment of advanced non-small cell lung cancer (NSCLC)" (Abstract #7165). This recognition is a testament to Nitto’s commitment and dedication to innovation and progress in the field of cancer research. Please stop by to explore our groundbreaking research firsthand! Should you have interest in collaborating or exploring partnership opportunities, please connect with our Nitto representatives at the conference or nittobiopharma.com. Let's work together to make a difference in the fight against cancer. #NittoBioPharma #CancerInnovation #ShortTalk #BusinessDevelopment #AACR #NSCLC

Repost from Nitto Americas: This Women's Herstory Month, we celebrate the incredible women who've shaped our past, present, and future. From breaking barriers to blazing trails, their resilience and determination inspire us all. Let's celebrate their achievements, amplify their voices, and continue striving for equality and empowerment. Together, we're writing a legacy of strength, courage, and boundless possibility. #EmpowerWomen #WomensHerstoryMonth

The Nitto Team looks forward to connecting with life science global leaders and colleagues at this year’s JP Morgan Healthcare Conference January 8 – 11th to discuss potential business partnering and licensing opportunities of its pipeline programs and drug delivery platform. Nitto has reserved a sponsorship suite within the BIO 1:1 Partnering Forum (https://bit.ly/3TPOY2R) located in the Golden Gate Ballroom A on Level 2 of the San Francisco Marriott Marquis Hotel (4th and Mission Streets; https://bit.ly/3TP0UBS). We look forward to dynamic presentations, workshops and discussions as we work together to bring novel medicines to patients and the community at large!

New Year, New Beginnings! Here's to a fresh start and exciting adventures in 2024. 🎉 🎉 🌟 #CheersToNewBeginnings #HappyNewYear

Winter has officially arrived! Get ready for a COZY season! #wintersolstice #nitto

Please join the Nitto scientific team in Philadelphia from November 2-5, 2023 at Kidney Week 2023, the American Society of Nephrology (ASN) Annual Conference, as they present two (2) posters supporting our Cedar (NBF-008) program targeting LPAR1 for the treatment of kidney fibrosis / chronic kidney disease. 📅 On November 4, 2023 | 10:00 AM– 12:00 PM | EXHIBIT HALL: Dr. Xing-Xian (Scott) Yu will be presenting (SA-PO443) "Targeting Lysophosphatidic Acid Receptor 1 (LPAR1) with siRNA-LNP Is a Potential Therapeutic Approach for CKD-Associated Kidney Fibrosis". The data demonstrates that Nitto has developed an LPAR1 siRNA-LNP asset, which efficiently delivers the siRNA to kidney cells causing significant inhibition of LPAR1 expression and improvement of kidney fibrosis and function in different rodent models of chronic kidney disease. The findings support its advance to clinical development. Dr. Yun Liu will be presenting (SA-PO442) "siRNA Inhibition of Lysophosphatidic Acid Receptor 1 (LPAR1) Attenuates Kidney Fibrosis and Improves Kidney Function in a Rat Model of Hypertensive CKD". The data demonstrates that inhibition of LPAR1 expression with above LPAR1 siRNA-LNP significantly improves kidney fibrosis and kidney function in hypertensive rats. This improvement is better than the current standard of care (SOC) when treated alone, whereas a combination treatment with the SOC shows an additive efficacy. These findings further support its advance to clinical development. https://bit.ly/46MUvLm #KidneyWeek2023 #AmericanSocietyofNephrologyAnnualConference #ASN #NittoBioPharma #siRNA #LNP #KidneyCells

We would like to thank our interns for their hard work during their time here at NBPI. They worked in a variety of arenas to impact our activities, including; new business and project management tools, assays to understand LNP properties, formulation optimization for enhanced nucleic acid delivery, etc. Amazing work everyone!